Stifel maintains Neurocrine Bio stock target, positive on Takeda deal
Neurocrine Biosciences Inc. (NASDAQ:NBIX) shares, currently trading at $148.19, maintained a positive outlook as Stifel ...
Neurocrine’s Strategic Partnership with Takeda: A Catalyst for Growth and Financial Upside
Stifel Nicolaus analyst Paul Matteis has maintained their bullish stance on NBIX stock, giving a Buy rating on January 24.Invest with ...
The Pharma Letter2d
Neurocrine revamps osavampator deal with Takeda
USA-based Neurocrine Biosciences yesterday revealed it has amended its agreement with Japanese pharma major Takeda to develop ...
BioSpace2d
Neurocine Gains ‘High-Risk/High-Reward’ Depression Asset From Takeda
Little information has emerged about osavampator, a potentially first-in-class drug, since its promising Phase II performance ...
Pharmabiz1d
Neurocrine Biosciences and Takeda amend strategic collaboration to develop and commercialize osavampator
Neurocrine Biosciences, Inc., is a leading neuroscience-focused, biopharmaceutical company, announced it has amended its agreement with Takeda to develop and commercialize osavampator (NBI-1065845/TAK ...
Neurocrine announces amendment to collaboration with Takeda
Neurocrine Biosciences (NBIX) announced it has amended its agreement with Takeda (TAK) to develop and commercialize osavampator. Under the ...